Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection

Haya Ascher-Svanum,1 Diego Novick,2,3 Josep Maria Haro,4 Jordan Bertsch,4 David McDonnell,1 Holland Detke11Eli Lilly and Company, Indianapolis, IN, USA; 2Eli Lilly and Company, Windlesham, Surrey, UK; 3Departament de Psiquiatria, Universitat Autonoma de Barcelona, Spain; 4Parc Sanitari Sant Joan de...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/12667f4e45cf4e3fa8a25fb83321066f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:12667f4e45cf4e3fa8a25fb83321066f
record_format	dspace
spelling	oai:doaj.org-article:12667f4e45cf4e3fa8a25fb83321066f2021-12-02T00:57:50ZLong-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection1178-2021https://doaj.org/article/12667f4e45cf4e3fa8a25fb83321066f2014-06-01T00:00:00Zhttp://www.dovepress.com/long-term-functional-improvements-in-the-2-year-treatment-of-schizophr-a17293https://doaj.org/toc/1178-2021 Haya Ascher-Svanum,1 Diego Novick,2,3 Josep Maria Haro,4 Jordan Bertsch,4 David McDonnell,1 Holland Detke11Eli Lilly and Company, Indianapolis, IN, USA; 2Eli Lilly and Company, Windlesham, Surrey, UK; 3Departament de Psiquiatria, Universitat Autonoma de Barcelona, Spain; 4Parc Sanitari Sant Joan de Déu, Centro de Investigación Biomédica en Red en el Área de Salud Mental, Universitat de Barcelona, Barcelona, SpainBackground: Little is known about the long-term changes in the functioning of schizophrenia patients receiving maintenance therapy with olanzapine long-acting injection (LAI), and whether observed changes differ from those seen with oral olanzapine.Methods: This study describes changes in the levels of functioning among outpatients with schizophrenia treated with olanzapine-LAI compared with oral olanzapine over 2 years. This was a secondary analysis of data from a multicenter, randomized, open-label, 2-year study comparing the long-term treatment effectiveness of monthly olanzapine-LAI (405 mg/4 weeks; n=264) with daily oral olanzapine (10 mg/day; n=260). Levels of functioning were assessed with the Heinrichs–Carpenter Quality of Life Scale. Functional status was also classified as “good”, “moderate”, or “poor”, using a previous data-driven approach. Changes in functional levels were assessed with McNemar’s test and comparisons between olanzapine-LAI and oral olanzapine employed the Student’s t-test. Results: Over the 2-year study, the patients treated with olanzapine-LAI improved their level of functioning (per Quality of Life total score) from 64.0–70.8 (P<0.001). Patients on oral olanzapine also increased their level of functioning from 62.1–70.1 (P<0.001). At baseline, 19.2% of the olanzapine-LAI-treated patients had a “good” level of functioning, which increased to 27.5% (P<0.05). The figures for oral olanzapine were 14.2% and 24.5%, respectively (P<0.001). Results did not significantly differ between olanzapine-LAI and oral olanzapine. Conclusion: In this 2-year, open-label, randomized study of olanzapine-LAI, outpatients with schizophrenia maintained or improved their favorable baseline level of functioning over time. Results did not significantly differ between olanzapine-LAI and oral olanzapine. Keywords: antipsychotics, functioning, olanzapine long-acting injection, quality of life, schizophreniaAscher-Svanum HNovick DHaro JMBertsch JMcDonnell DDetke HDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2014, Iss default, Pp 1125-1131 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Ascher-Svanum H Novick D Haro JM Bertsch J McDonnell D Detke H Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
description	Haya Ascher-Svanum,1 Diego Novick,2,3 Josep Maria Haro,4 Jordan Bertsch,4 David McDonnell,1 Holland Detke11Eli Lilly and Company, Indianapolis, IN, USA; 2Eli Lilly and Company, Windlesham, Surrey, UK; 3Departament de Psiquiatria, Universitat Autonoma de Barcelona, Spain; 4Parc Sanitari Sant Joan de Déu, Centro de Investigación Biomédica en Red en el Área de Salud Mental, Universitat de Barcelona, Barcelona, SpainBackground: Little is known about the long-term changes in the functioning of schizophrenia patients receiving maintenance therapy with olanzapine long-acting injection (LAI), and whether observed changes differ from those seen with oral olanzapine.Methods: This study describes changes in the levels of functioning among outpatients with schizophrenia treated with olanzapine-LAI compared with oral olanzapine over 2 years. This was a secondary analysis of data from a multicenter, randomized, open-label, 2-year study comparing the long-term treatment effectiveness of monthly olanzapine-LAI (405 mg/4 weeks; n=264) with daily oral olanzapine (10 mg/day; n=260). Levels of functioning were assessed with the Heinrichs–Carpenter Quality of Life Scale. Functional status was also classified as “good”, “moderate”, or “poor”, using a previous data-driven approach. Changes in functional levels were assessed with McNemar’s test and comparisons between olanzapine-LAI and oral olanzapine employed the Student’s t-test. Results: Over the 2-year study, the patients treated with olanzapine-LAI improved their level of functioning (per Quality of Life total score) from 64.0–70.8 (P<0.001). Patients on oral olanzapine also increased their level of functioning from 62.1–70.1 (P<0.001). At baseline, 19.2% of the olanzapine-LAI-treated patients had a “good” level of functioning, which increased to 27.5% (P<0.05). The figures for oral olanzapine were 14.2% and 24.5%, respectively (P<0.001). Results did not significantly differ between olanzapine-LAI and oral olanzapine. Conclusion: In this 2-year, open-label, randomized study of olanzapine-LAI, outpatients with schizophrenia maintained or improved their favorable baseline level of functioning over time. Results did not significantly differ between olanzapine-LAI and oral olanzapine. Keywords: antipsychotics, functioning, olanzapine long-acting injection, quality of life, schizophrenia
format	article
author	Ascher-Svanum H Novick D Haro JM Bertsch J McDonnell D Detke H
author_facet	Ascher-Svanum H Novick D Haro JM Bertsch J McDonnell D Detke H
author_sort	Ascher-Svanum H
title	Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
title_short	Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
title_full	Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
title_fullStr	Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
title_full_unstemmed	Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
title_sort	long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/12667f4e45cf4e3fa8a25fb83321066f
work_keys_str_mv	AT aschersvanumh longtermfunctionalimprovementsinthe2yeartreatmentofschizophreniaoutpatientswitholanzapinelongactinginjection AT novickd longtermfunctionalimprovementsinthe2yeartreatmentofschizophreniaoutpatientswitholanzapinelongactinginjection AT harojm longtermfunctionalimprovementsinthe2yeartreatmentofschizophreniaoutpatientswitholanzapinelongactinginjection AT bertschj longtermfunctionalimprovementsinthe2yeartreatmentofschizophreniaoutpatientswitholanzapinelongactinginjection AT mcdonnelld longtermfunctionalimprovementsinthe2yeartreatmentofschizophreniaoutpatientswitholanzapinelongactinginjection AT detkeh longtermfunctionalimprovementsinthe2yeartreatmentofschizophreniaoutpatientswitholanzapinelongactinginjection
_version_	1718403362611789824

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection

Ejemplares similares